This study was conducted in compliance with all regulatory obligations as well as the institutional review board and informed consent regulations at each investigational site.
Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation
Version of Record online: 9 APR 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 19, Issue 6, pages 594–601, June 2013
How to Cite
Teperman, L. W., Poordad, F., Bzowej, N., Martin, P., Pungpapong, S., Schiano, T., Flaherty, J., Dinh, P., Rossi, S., Subramanian, G. M. and Spivey, J. (2013), Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl, 19: 594–601. doi: 10.1002/lt.23628
Lewis W. Teperman and Thomas Schiano have received research grants from Gilead Sciences, Inc.; Lewis W. Teperman has served as a speaker. Fred Poordad has served on advisory boards and as a speaker and has received research grants and unrestricted grants from Gilead Sciences. Natalie Bzowej has served in an advisory capacity for Gilead Sciences. Paul Martin has received unrestricted grants from Gilead Sciences. John Flaherty, Phillip Dinh, Stephen Rossi, and G. Mani Subramanian are employees of Gilead Sciences. Surakit Pungpapong and James Spivey have nothing to disclose.
This study was sponsored by Gilead Sciences, Inc. In collaboration with the investigators, Gilead Sciences designed the study, conducted statistical analyses, and interpreted the data, which Gilead Sciences holds. The authors had unrestricted access to the primary data and were not limited by Gilead Sciences in the writing of this article. The corresponding author (Lewis W. Teperman) takes full responsibility for the veracity of the data and the statistical analysis.
- Issue online: 28 MAY 2013
- Version of Record online: 9 APR 2013
- Accepted manuscript online: 27 FEB 2013 03:07PM EST
- Manuscript Accepted: 13 FEB 2013
- Manuscript Received: 28 SEP 2012
Additional Supporting Information may be found in the online version of this article.
|lt23628-sup-0001-suppinfo.rtf||21K||Supporting Table 1. Treatment-Emergent Grade 3-4 Laboratory Abnormalities in Two or More Patients|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.